258121 Barriers to cervical cancer screening among Korean women and use of the HPV vaccine for daughters and sons

Sunday, October 28, 2012

Lourdes Baezconde-Garbanati, PhD, MPH , Department of Preventive Medicine, Institute for Health Promotion & Disease Prevention Research, University of Southern California, Los Angeles, CA
Nan ZHao, MPH , Annenberg School for Communication and Journalism, University of Southern California, Los Angeles, CA
Jimi Huh , Department of Preventive Medicine, University of Southern California, Alhambra, CA
Sheila Murphy, PhD , Annenberg School of Communication and Journalism, University of Southern California, Los Angeles, CA
Meghan Bridgid Moran, PhD , School of Communication, San Diego State University, San Diego, CA
Lauren B. Frank, PhD , Department of Communication, Portland State University, Portland, OR
Joyee S. Chatterjee, PhD , Annenberg School for Communication and Journalism, University of Southern California, Marina del Rey, CA
BACKGROUND: With early detection and the advent of the Human Papilloma Virus (HPV) vaccine, cervical cancer is both a curable and preventable disease. But less than half of Korean women get a regular Pap test or follow guidelines for screening. Moreover, although a vaccine to prevent common strains of HPV is available for males and females ages 9 to 26, little is known regarding acceptance of the HPV vaccine in the Korean population. PURPOSE: This study describes Korean women's knowledge, attitudes, beliefs and perceived barriers to cervical cancer screening; attitudes toward vaccines in general, and toward having their daughter or son vaccinated against HPV. METHODS: Over 50 in depth telephone interviews using random digit dialing were conducted with English-speaking Korean American women, ages of 25 to 45. RESULTS: Analysis show that Korean women generally lack information regarding Pap tests, are uncertain about the connection between HPV and cervical cancer, and are unclear on the availability of the HPV vaccine. Respondents reported structural, financial, personal and cultural barriers toward use of the vaccine. Safety concerns and lack of sufficient information regarding the HPV vaccine were the most commonly mentioned barriers. Interestingly, a significantly higher proportion of Korean mothers would provide the HPV vaccine to a 13 year-old daughter than to a son of the same age. DISCUSSION: To address cervical cancer disparities among Korean women, early preventative cancer information should address barriers to screening and encourage HPV vaccine use among both Korean girls and boys.

Learning Areas:
Administer health education strategies, interventions and programs
Diversity and culture
Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs
Protection of the public in relation to communicable diseases including prevention or control
Public health or related education

Learning Objectives:
1. By the end of the session, participants will be able to explain barriers to cervical cancer screening among Korean women and use of the HPV vaccine among their daughters and sons. 2. By the end of the session, participants will be able to identify ways to reduce cervical cancer disparities in this population.

Keywords: Cervical Cancer, Screening

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am one of two Principal Investigators (Murphy/Baezconde-Garbanati) on a study funded by the National Cancer Institute to assess knowledge, attitudes, beliefs, and behaviors to cervical cancer screening and use of the HPV vaccine among vulnerable ethnic populations, including Korean women. For the last 20 years, my research has focused on the elimination of cancer-related disparities. I have a strong record of extramural funding and I am widely published in peer-reviewed journals.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.